News | September 10, 2007

Carestream Highlights New Dyes for In Vivo Imaging

September 11, 2007 - Carestream Molecular Imaging, a division of Carestream Health Inc., announced at the Joint Molecular Imaging Conference the introduction of new large Stokes shift dyes for fluorescent in vivo imaging applications, KODAK X-SIGHT Large Stokes Shift Dyes, which are reactive dyes designed to enable researchers and scientists to maximize the fluorescent signal while minimizing auto-fluorescence issues during in vivo imaging.
“Stokes shift” refers to the separation of absorption and emission maxima. Having a significantly larger Stokes shift—greater than 80 nanometers in the case of KODAK X-SIGHT Dyes—helps researchers eliminate much of the background that typically obstructs the fluorescent signal while allowing researchers to excite and emit the dyes at their maxima, thus resulting in far greater signal to noise. Most commercially available dyes typically have a Stokes shift between 20-30 nanometers.
In an organism, the KODAK X-SIGHT Dyes can illuminate a region of interest when excited by the appropriate wavelength of fluorescent light, thus allowing the researcher to visualize their target. While the KODAK X-SIGHT Imaging Agents have been optimized for KODAK Image Station and In-Vivo Systems, they are also compatible with other commercially available digital imaging systems.
“Our new KODAK X-SIGHT Large Stokes Shift Dyes, characterized by near infrared emission and a large Stokes shift, enable researchers to achieve a higher sensitivity of fluorescent detection deeper into tissue,” said Shahram Hejazi, PhD, President of Carestream Molecular Imaging. “With superior performance when compared to other commercially available products, these new dyes validate our outstanding dye chemistry expertise and leadership in fluorescent imaging.”
KODAK X-SIGHT Dyes will be available this fall for preclinical use.

For more information: www.MIStore.carestreamhealth.com and www.carestreamhealth.com

Related Content

Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
ACR Introduces New Contrast Reaction Card
News | Contrast Media | February 07, 2018
The American College of Radiology (ACR) introduced a new contrast reaction card that summarizes important steps to be...
Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Overlay Init